Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,048.00
Ask: 12,052.00
Change: -106.00 (-0.87%)
Spread: 4.00 (0.033%)
Open: 12,092.00
High: 12,098.00
Low: 12,036.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Ashtead Rises On Strong Earnings And Buyback Plans

Tue, 18th Jun 2019 08:49

(Alliance News) - Stock prices in London opened flat on Tuesday, with Ashtead rising after strong annual results, helping the FTSE 100 to outperform other European indices.The UK blue-chip index was up just 3.58 points at 7,360.68. The mid-cap FTSE 250 was down 51.10 points, or 0.3%, at 19,106.51. The AIM All-Share was up 0.17 point at 937.63.The Cboe UK 100 index was up 0.1% at 12,496.39. The Cboe UK 250 was down 0.1% at 17,165.89, and the Cboe UK Small Companies was flat at 11,647.12.In European equities, the CAC 40 stock index in Paris was down 0.1% and the DAX 30 in Frankfurt was down 0.6%.In the FTSE 100, Ashtead Group was up 0.7%, after the equipment rentals firm reporting a strong set of annual results for financial 2019, while also announcing plans for a GBP500 million share buyback.For the financial year ended April 30, revenue rose 19% to GBP4.49 billion from GBP3.71 billion the year before, and pretax profit rose 20% to GBP1.06 billion from GBP862.1 million. The company said it continued to enjoy strong end-markets in North America and was executing well on its strategy of organic growth supported by targeted bolt-on acquisitions.Ashtead proposed a final dividend of 33.5 pence, bringing a total payout 40.0 pence, up 21% from 33.0p in financial 2018.Interactive Investor's Richard Hunter said: "It is the company's very reliance on the US which tends to spook investors, however. Given Ashtead's previous mauling during the financial crisis following a sharp downturn in the construction space, it seems that investors may have been once bitten and twice shy. "Net debt remains high at around GBP4 billion which, whilst currently containable given the group's cash generation, would prove to be an immediate noose in the event of a downturn in the US, which on a wider basis is the current topic of debate given some mixed economic numbers of late. In addition, such an acquisitive nature always carries execution risk, while from an investment perspective the dividend yield of around 2% still seems uninviting."AstraZeneca was up 0.5% after the Anglo-Swedish drugmaker and Merck & Co said the European Commission has approved Lynparza as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.At the other end of the large cap index, Evraz was the worst performer, down 2.2% after Citigroup downgraded the Russian steelmaker to Sell from Neutral. InterContinental Hotels Group was down 1.9% after Barclays cut the hotel operator to Underweight from Equal Weight. In the FTSE 250, Telecom Plus was the best performer, up 2.5%. The multi utility services provider said it delivered annual results for financial 2019 in line with expectations. For the year ended March 31, revenue rose 1.5% to GBP804.4 million from GBP792.9 million the year before, and pretax profit increased 4.9% to GBP43.0 million from GBP41.0 million. Adjusted pretax profit increased by 3.7% to GBP56.3 million from GBP54.3 million in 2018. The company said that in the absence of "unforeseen circumstances" it expect adjusted pretax profit for financial 2020 to be between GBP60 million and GBP65 million. The US Federal Reserve's policy-setting Federal Open Market Committee, which is scheduled to meet later on Tuesday and Wednesday, is widely expected to hold interest rates unchanged this month, although it is very likely to signal a rate cut sometime in the near term. The policy announcement is due at 1900 BST on Wednesday."Tomorrow's FOMC hangs over the markets, and today ought to be quiet, but there's an air of nervousness around," noted Societe Generale's Kit Juckes. The Japanese Nikkei 225 index closed down 0.7%. In China, the Shanghai Composite closed up 0.1%, while the Hang Seng index in Hong Kong is up 1.2%.The pound was quoted at USD1.2538 Tuesday, lower than USD1.2559 at the London equities close Monday.The battle for the Conservative party crown in the UK is revving up with a fresh round of voting in the leadership stakes as Boris Johnson is due to break cover and take part in television debates.Tory MPs will vote in the second bout of the contest to select the UK's next prime minister on Tuesday ahead of a live TV debate that will feature the front-runner and former foreign secretary, Johnson.Candidates need to gain at least 33 votes from MPs to remain in the race to reach the final run-off, which will see some 160,000 Tory members select the next prime minister.If all candidates pass the 33-vote threshold, the one with the lowest total will be eliminated and by the end of the week, four of the six current riders will be forced out, leaving the final two to go head-to-head for votes from the Tory grassroots.The economic events calendar on Tuesday has eurozone inflation readings at 1000 BST and US housing starts at 1330 BST. In addition, European Central Bank President Mario Draghi and Bank of England Governor Mark Carney will speak on the second day of the ECB's annual three-day forum in Sintra, Portugal at 0900 BST and 1500 BST, respectively.

More News
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.